The dynamics of the Philips Respironics recall (WSJ: Roland, D, 8/17/21) requires all sleep physicians to consider non-CPAP therapies for patients diagnosed with Obstructive Sleep Apnea (OSA).  The timeline for Philips to rectify their situation due to foam degradation and its consequences is unknown.  Currently, ResMed PAP related devices are on backlog.  Additionally, many of the 3 million patients affected by this recall may be reluctant to try CPAP again or simply prefer alternative treatment.

The current recommendation by Philips is to immediately stop using their CPAP or BiPAP affected by this foam degeneration and seek alternative treatment.  Oral Appliance Therapy (OAT) is the most common recommended alternative treatment.  Currently, OAT is utilized in only 5% of the patients with OSA in the US while in some European countries more than 50% of patients with OSA are treated with Oral Appliance Therapy as the primary form of treatment.

The American Academy of Dental Sleep Medicine (AADSM) has alerted all its members to accelerate the process of getting patients treated with OAT and has responded to this crisis on their website (www.aadsm.org).  The advent of telemedicine, disposable Home Sleep Testing (HST) and Precision Custom Designed Oral Appliances may all be employed to provide the best care and transition of patients with OSA from their recalled CPAP machines.  There has never been a better time to consider and utilize OAT for patients with Obstructive Sleep Apnea.  All patients affected by this recall should immediately consult their healthcare professionals about prescribing Oral Appliance Therapy.

Edward T Sall MD DDS MBA

Medical Director-ProSomnus Sleep Technologies

Medical Director-BetterNight Sleep Solutions